Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.65
IDXX's Cash to Debt is ranked higher than
52% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. IDXX: 0.65 )
IDXX' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 0.65

Equity to Asset 0.42
IDXX's Equity to Asset is ranked higher than
53% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. IDXX: 0.42 )
IDXX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.89
Current: 0.42

0.42
0.89
Interest Coverage 49.53
IDXX's Interest Coverage is ranked higher than
60% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. IDXX: 49.53 )
IDXX' s 10-Year Interest Coverage Range
Min: 32.59   Max: 9999.99
Current: 49.53

32.59
9999.99
F-Score: 5
Z-Score: 8.79
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 19.37
IDXX's Operating margin (%) is ranked higher than
92% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. IDXX: 19.37 )
IDXX' s 10-Year Operating margin (%) Range
Min: -1.67   Max: 20.3
Current: 19.37

-1.67
20.3
Net-margin (%) 13.64
IDXX's Net-margin (%) is ranked higher than
90% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. IDXX: 13.64 )
IDXX' s 10-Year Net-margin (%) Range
Min: -8.02   Max: 14.26
Current: 13.64

-8.02
14.26
ROE (%) 36.24
IDXX's ROE (%) is ranked higher than
98% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. IDXX: 36.24 )
IDXX' s 10-Year ROE (%) Range
Min: -6.97   Max: 36.24
Current: 36.24

-6.97
36.24
ROA (%) 15.26
IDXX's ROA (%) is ranked higher than
96% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. IDXX: 15.26 )
IDXX' s 10-Year ROA (%) Range
Min: -5.6   Max: 16.74
Current: 15.26

-5.6
16.74
ROC (Joel Greenblatt) (%) 58.69
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. IDXX: 58.69 )
IDXX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3.19   Max: 91.39
Current: 58.69

-3.19
91.39
Revenue Growth (%) 11.20
IDXX's Revenue Growth (%) is ranked higher than
81% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. IDXX: 11.20 )
IDXX' s 10-Year Revenue Growth (%) Range
Min: 8.4   Max: 23.1
Current: 11.2

8.4
23.1
EBITDA Growth (%) 12.50
IDXX's EBITDA Growth (%) is ranked higher than
84% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. IDXX: 12.50 )
IDXX' s 10-Year EBITDA Growth (%) Range
Min: -31.8   Max: 98.1
Current: 12.5

-31.8
98.1
EPS Growth (%) 13.70
IDXX's EPS Growth (%) is ranked higher than
83% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. IDXX: 13.70 )
IDXX' s 10-Year EPS Growth (%) Range
Min: -0.8   Max: 26.4
Current: 13.7

-0.8
26.4
» IDXX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

IDXX Guru Trades in Q1 2013

Paul Tudor Jones 4,300 sh (New)
Jim Simons 348,852 sh (+609.74%)
Steven Cohen 18,435 sh (+135.86%)
Jeremy Grantham 45,990 sh (+4.31%)
Ruane Cunniff 5,288,711 sh (+0.04%)
Bill Frels 2,286 sh (unchged)
Jean-Marie Eveillard 3,500 sh (unchged)
Ron Baron 2,961,742 sh (-0.25%)
Chris Davis 183,123 sh (-2.2%)
Meridian Funds 360,000 sh (-5.01%)
Chuck Royce 1,959,801 sh (-16.4%)
» More
Q2 2013

IDXX Guru Trades in Q2 2013

Joel Greenblatt 3,837 sh (New)
Ron Baron 3,584,998 sh (+21.04%)
Jean-Marie Eveillard 4,000 sh (+14.29%)
Jeremy Grantham 46,690 sh (+1.52%)
Ruane Cunniff 5,351,762 sh (+1.19%)
Meridian Funds 360,000 sh (unchged)
Steven Cohen Sold Out
Bill Frels Sold Out
Chris Davis 179,794 sh (-1.82%)
Jim Simons 342,452 sh (-1.83%)
Chuck Royce 1,634,911 sh (-16.58%)
Paul Tudor Jones 3,000 sh (-30.23%)
» More
Q3 2013

IDXX Guru Trades in Q3 2013

Steven Cohen 7,100 sh (New)
Ron Baron 3,688,385 sh (+2.88%)
Jean-Marie Eveillard 4,000 sh (unchged)
Paul Tudor Jones Sold Out
Ruane Cunniff 5,344,172 sh (-0.14%)
Chris Davis 168,443 sh (-6.31%)
Chuck Royce 1,493,311 sh (-8.66%)
Jeremy Grantham 39,890 sh (-14.56%)
Joel Greenblatt 2,953 sh (-23.04%)
Jim Simons 118,700 sh (-65.34%)
» More
Q4 2013

IDXX Guru Trades in Q4 2013

Bill Frels 4,999 sh (New)
Paul Tudor Jones 2,407 sh (New)
Steven Cohen 8,891 sh (+25.23%)
Ron Baron 3,727,807 sh (+1.07%)
Chris Davis 169,541 sh (+0.65%)
Chuck Royce 1,495,311 sh (+0.13%)
Jean-Marie Eveillard 4,000 sh (unchged)
Ruane Cunniff 5,271,088 sh (-1.37%)
Joel Greenblatt 2,834 sh (-4.03%)
Jeremy Grantham 37,423 sh (-6.18%)
Jim Simons 73,552 sh (-38.04%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-09-30 Reduce -23.04%$88.73 - $99.19 $ 117.9423%2953
Ron Baron 2013-06-30 Add 21.04%0.3%$82.44 - $91 $ 117.9435%3584998
Joel Greenblatt 2013-06-30 New Buy0.02%$82.44 - $91 $ 117.9435%3837
Meridian Funds 2012-09-30 Reduce -23.09%0.42%$87.21 - $100 $ 117.9426%427500
Meridian Funds 2012-06-30 Add 7.33%0.12%$82.04 - $95.92 $ 117.9435%555820
John Hussman 2012-03-31 Sold Out 0.06%$78.98 - $89.03 $ 117.9448%0
John Hussman 2011-09-30 Reduce -69.33%0.13%$71.13 - $86.97 $ 117.9453%46000
Ray Dalio 2011-09-30 Sold Out 0.05%$71.13 - $86.97 $ 117.9453%0
Meridian Funds 2011-06-30 Add 33.66%0.3%$72.42 - $82.4 $ 117.9451%517615
John Hussman 2011-06-30 Reduce -57.51%0.26%$72.42 - $82.4 $ 117.9451%150000
Ruane Cunniff 2011-03-31 Reduce -24.41%1.78%$68.48 - $79.33 $ 117.9459%7509464
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Idexx Laboratories

Baron Funds Comments on IDEXX Laboratories - Feb 06, 2013

Shares of IDEXX Laboratories, Inc. (IDXX), a leading supplier of diagnostic products and tools to the veterinary market, retreated from all-time highs after the company modestly reduced its 2012 revenue expectations. Nevertheless, management provided better than expected revenue guidance for 2013. We remain excited about the company's significant long-term opportunity in veterinary diagnostics and testing. We believe the confluence of the company's emerging new technology platform, its escalating pace of new product introduction, secular trends toward wellness testing for pets, and a modest economic tailwind driving more traffic to veterinarians will lead to accelerating growth in 2013 and beyond.

From Baron Funds' fourth quarter letter.


Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Aug 23, 2012

From Baron Funds' second-quarter letter:

Shares of IDEXX Laboratories, Inc. (IDXX), the leading provider of diagnostics to the veterinary industry, rose during the quarter, driven by improving domestic veterinary trends and progress on resolving an ongoing FTC investigation of its distribution practices. IDEXX reported that domestic foot traffic to veterinarians and practice-level revenues grew year-over-year. The company also announced a revenue-neutral plan to amend its contract with one of its three large distributors, which it believes will alleviate the FTC's concerns.
Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 34.20
IDXX's P/E(ttm) is ranked lower than
52% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. IDXX: 34.20 )
IDXX' s 10-Year P/E(ttm) Range
Min: 15.21   Max: 44.22
Current: 34.2

15.21
44.22
P/B 11.90
IDXX's P/B is ranked lower than
83% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. IDXX: 11.90 )
IDXX' s 10-Year P/B Range
Min: 3.13   Max: 12.8
Current: 11.9

3.13
12.8
P/S 4.60
IDXX's P/S is ranked lower than
55% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. IDXX: 4.60 )
IDXX' s 10-Year P/S Range
Min: 1.75   Max: 5.01
Current: 4.6

1.75
5.01
PFCF 38.00
IDXX's PFCF is ranked lower than
75% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. IDXX: 38.00 )
IDXX' s 10-Year PFCF Range
Min: 12.56   Max: 240
Current: 38

12.56
240
EV-to-EBIT 23.80
IDXX's EV-to-EBIT is ranked lower than
55% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. IDXX: 23.80 )
IDXX' s 10-Year EV-to-EBIT Range
Min: 10.7   Max: 31.8
Current: 23.8

10.7
31.8
PEG 2.60
IDXX's PEG is ranked higher than
60% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. IDXX: 2.60 )
IDXX' s 10-Year PEG Range
Min: 0.77   Max: 2.77
Current: 2.6

0.77
2.77
Shiller P/E 43.20
IDXX's Shiller P/E is ranked lower than
56% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. IDXX: 43.20 )
IDXX' s 10-Year Shiller P/E Range
Min: 20.68   Max: 67.08
Current: 43.2

20.68
67.08

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.00
IDXX's Price/Tangible Book is ranked lower than
86% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. IDXX: 22.00 )
IDXX' s 10-Year Price/Tangible Book Range
Min: 1.98   Max: 19.81
Current: 22

1.98
19.81
Price/DCF (Projected) 2.80
IDXX's Price/DCF (Projected) is ranked lower than
58% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. IDXX: 2.80 )
IDXX' s 10-Year Price/DCF (Projected) Range
Min: 1.74   Max: 3.07
Current: 2.8

1.74
3.07
Price/Median PS Value 1.20
IDXX's Price/Median PS Value is ranked higher than
59% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. IDXX: 1.20 )
IDXX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 2.31
Current: 1.2

0.48
2.31
Price/Peter Lynch Fair Value 2.60
IDXX's Price/Peter Lynch Fair Value is ranked higher than
50% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. IDXX: 2.60 )
IDXX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.99   Max: 2.34
Current: 2.6

0.99
2.34
Price/Graham Number 5.60
IDXX's Price/Graham Number is ranked lower than
75% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. IDXX: 5.60 )
IDXX' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 5.49
Current: 5.6

1.4
5.49
Earnings Yield (Greenblatt) 4.20
IDXX's Earnings Yield (Greenblatt) is ranked higher than
53% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. IDXX: 4.20 )
IDXX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 9.4
Current: 4.2

3.1
9.4
Forward Rate of Return (Yacktman) 14.85
IDXX's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. IDXX: 14.85 )
IDXX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 14.5   Max: 22.9
Current: 14.85

14.5
22.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:IX1.Germany
Idexx Laboratories, a Delaware corporation, was incorporated in 1983. The Company develop, manufacture and distribute products and provide services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its product and services includes point-of-care veterinary diagnostic products, veterinary reference laboratory diagnostic and consulting services, practice management systems and services and digital radiography systems, as well as biological materials testing and laboratory diagnostic instruments and services, among others. Its operations are segmented into three namely - CAG, Water, LPD, and Other. CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the bioresearch market, primarily related to diagnostics and information management. Water segment develops, designs, manufactures and distributes a range of products used in the detection of various microbiological parameters in water. LPD segment develops, designs, manufactures and distributes diagnostic tests and related instrumentation that are used to detect a wide range of diseases and to monitor health status in livestock and poultry. The Other segment is comprised of Dairy and OPTI Medical operating segments and a product line and out-licensing arrangements remaining from pharmaceutical business. Dairy segment develops, designs, manufactures and distributes products to detect contaminants in milk. OPTI Medical develops, designs, manufactures, and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. Further, OPTI Medical manufactures VetStat Electrolyte and Blood Gas Analyzer and electrolyte consumables used with its Catalyst Dx analyzer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide